• The University is our administrative home as well as providing infrastracture and all of the support you’d expect from such a great University.

  • Prostate Cancer UK support the majority of our work on identifying and validating biomarkers for diagnosing prostate cancer earlier and establishing which cancers are more aggressive and will require treatment.

  • The Urology Foundation generously fund a large project and staff in our lab to allow us to further our work on the prostate biomarker NAALADL2. In particular we are focusing on how we can best use NAALADL2 for patient benefit.

  • The Alan Moremont Memorial Fund support our work on a very promising novel biomarker for early diagnosis cholangiocarcinoma, or cancer of the bile duct. This cancer tends to have poor outcome and we believe our novel marker has the potential to make a real impact by facilitating early diagnosis and improvements in survival. We are also developing this marker as a therapeutic target to be used to treat cancer.

  • CRUK previously funded the lab infrastructure and some of the staff thus contributing to ongoing work. We continue to collaborate closely with our CRUK colleagues.They also support the prostate International Cancer Genome Consortium project which is funded by the Dallaglio Foundation.

The University is our administrative home as well as providing infrastracture and all of the support you’d expect from such a great University.

Prostate Cancer UK support the majority of our work on identifying and validating biomarkers for diagnosing prostate cancer earlier and establishing which cancers are more aggressive and will require treatment.

The Urology Foundation generously fund a large project and staff in our lab to allow us to further our work on the prostate biomarker NAALADL2. In particular we are focusing on how we can best use NAALADL2 for patient benefit.

The Alan Moremont Memorial Fund support our work on a very promising novel biomarker for early diagnosis cholangiocarcinoma, or cancer of the bile duct. This cancer tends to have poor outcome and we believe our novel marker has the potential to make a real impact by facilitating early diagnosis and improvements in survival. We are also developing this marker as a therapeutic target to be used to treat cancer.

CRUK previously funded the lab infrastructure and some of the staff thus contributing to ongoing work. We continue to collaborate closely with our CRUK colleagues.They also support the prostate International Cancer Genome Consortium project which is funded by the Dallaglio Foundation.